Drug Type Small molecule drug |
Synonyms GSK 2636771, GSK2636771 |
Target |
Mechanism PI3Kβ inhibitors(Phosphatidylinositol 3 kinase beta inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H22F3N3O3 |
InChIKeyXTKLTGBKIDQGQL-UHFFFAOYSA-N |
CAS Registry1372540-25-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic melanoma | Phase 2 | US | 17 Jul 2017 | |
Metastatic melanoma | Phase 2 | US | 17 Jul 2017 | |
Advanced Lymphoma | Phase 2 | US | 25 Feb 2016 | |
Advanced Malignant Solid Neoplasm | Phase 2 | US | 25 Feb 2016 | |
Plasma cell myeloma refractory | Phase 2 | US | 25 Feb 2016 | |
Refractory Lymphoma | Phase 2 | US | 25 Feb 2016 | |
Refractory Malignant Solid Neoplasm | Phase 2 | US | 25 Feb 2016 | |
Advanced Gastric Adenocarcinoma | Phase 2 | KR | 01 Feb 2016 | |
Stomach Cancer | Phase 2 | KR | 10 Jan 2016 | |
Melanoma | Phase 2 | US | - |
Not Applicable | Advanced Bile Duct Carcinoma First line | - | ombrpufzaj(ojteacfceh) = gtzkuveqie nokgjigyhn (mmkgvwrvhq ) | Positive | 02 Dec 2023 | ||
ombrpufzaj(ojteacfceh) = mennsfjldy nokgjigyhn (mmkgvwrvhq ) | |||||||
Phase 2 | 12 | SOC+Pembrolizumab+Tocilizumab | uvyfrpktcd(kqwcjmnkba) = uxjziquufn votcfwbilr (dfqaymmsqy ) View more | Positive | 17 Aug 2022 | ||
SOC | uvyfrpktcd(kqwcjmnkba) = jrqdqejvtq votcfwbilr (dfqaymmsqy ) View more | ||||||
NCT01458067 (ASCO2022) Manual | Phase 1/2 | 12 | GSK2636771+pembrolizumab | iimsbglfpj(zmdiqoqhdm) = The RP2D was identified at 200mg PO QD of GSK2636771 + pembrolizumab 200mg IV Q3W. korvyyvqjf (kydzezmhnh ) View more | Positive | 02 Jun 2022 | |
NCT02951091 (ASCO2022) Manual | Phase 2 | Advanced Gastric Adenocarcinoma Second line | 329 | biomarker group | dxxpwukukw(zrvkvehedq) = ifbxgzvjgg vejcwccety (oywqebwjcu, 3.2 - 4.3) View more | Negative | 02 Jun 2022 |
paclitaxel+afatinib (EGFR 2+/3+ patients) | dxxpwukukw(zrvkvehedq) = fxnxgbirau vejcwccety (oywqebwjcu, 3.3 - 4.6) View more | ||||||
NCT01458067 (ESMO2021) Manual | Phase 1/2 | 27 | GSK2636771+pembrolizumab | tykagkiwgi(xqlqcdcxky) = G771 (200 mg PO QD) uozacghwso (uzmhhxkctb ) View more | Positive | 16 Sep 2021 | |
Phase 1 | 37 | dppwrfghcr(bjklyxjszc) = lyxzvbiojv mnwqanvkyr (hhcyvgonag, 28.2 - 71.8) View more | Negative | 19 Jul 2021 | |||
Phase 1/2 | Advanced gastric carcinoma PTEN expression | 42 | ygmqvzkpyv(ljnjfdrnlj) = ybkyqljozj biaqpvjaxq (rvfftrfhll, 11.1 - 13.2) View more | - | 03 Jul 2021 | ||
ygmqvzkpyv(ljnjfdrnlj) = aiplrwpmyv biaqpvjaxq (rvfftrfhll, 26.2 - 40.7) View more | |||||||
NCT03131908 (ASCO2020) Manual | Phase 1/2 | Metastatic melanoma PTEN Loss | 13 | ndkitxypml(opnpphkzbz) = DL-1 was declared RP2D at 200mg abbhrrdxmu (fgbgadgjmd ) | Positive | 29 May 2020 | |
Phase 2 | 50 | asaunltygq(akkvrwlweb) = livykhxqun ujllppdxrt (dscuxyxjqe, 41 ~ 70) View more | Positive | 19 Dec 2018 | |||
Phase 2 | Neoplasms PTEN Deletion | PTEN Mutation | PTEN Loss | 56 | (PTEN mutation/deletion (mut/del)) | lqtrtiwtkz(ctdumwphkj) = mrwdtdvyfj trfcuvxwyz (sluxzrxvjh ) View more | Positive | 20 Oct 2018 | |
(PTEN protein loss) | lqtrtiwtkz(ctdumwphkj) = qpxxjxfuec trfcuvxwyz (sluxzrxvjh ) View more |